SMYD3 and neoplasm: In addition, since SMYD3 has been implicated in CHK2 phosphorylation (Fig. 5A, B), which is a marker of resistance and has previously been detected in resistant RC tissues (Fig. 5C), we analyzed its levels in AOM/DSS-induced mice tumor samples treated with irinotecan in combination or not with EM127.